Industry Outlook

The premature ejaculation treatment market is growth at a compound annual growth rate (CAGR) of 8.8% during the forecast period from 2024 to 2032. According to the research survey conducted by the International Journal of Impotence Research (IJIR), 30% adult men throughout the globe suffer with premature ejaculation. The prevalence rate of premature ejaculation varies across geographical and socio-cultural population. Premature ejaculation has been understood to cause a negative impact on the sexual satisfaction in men and their sexual partners.

People suffering with premature ejaculation are less likely to seek medical help, thus making it of utmost importance to raise awareness and acceptance of this disorder in patients and physicians. Existence of developed healthcare infrastructure and rising prevalence of premature ejaculation disorder drive the market growth in North America. Presence of matured generic drug market and increasing awareness of premature ejaculation propel the market growth in Asia Pacific.

Impressive pharmacodynamic properties exerted by SSRI’s make it drug of first choice for premature ejaculation treatment

Selective serotonin reuptake inhibitors are prescribed as the first line drug therapy for treatment of premature ejaculation. The mechanism of action involved is delayed ejaculation due to limited reabsorption of serotonin at the presynaptic neuron cells and increasing the serotonin levels at the postsynaptic receptors. The drugs prescribed as SSRI’s are sertraline, paroxetine, fluoxetine and citalopram. Topical anesthetic agents are set to project impressive growth during the forecast period 2024 to 2032. Currently Fortacin™ a eutectic mixture of Lidocaine and Prilocaine is being used as a topical aerosol formulation to decrease sensitivity of glans penis and increase the intravaginal ejaculation latency time. The topical anesthetic agents have better patient compliance and excellent sexual satisfaction in patients suffering with premature ejaculation.

Faster onset on action and low price makes oral route of administration popular among patients suffering with acute premature ejaculation

Prescribed drugs such as SSRI’s, tricyclic antidepressant, Phosphodiesterase type 5 inhibitors and beta-adrenergic blockers are taken by oral route of administration. Quick response time and availability at low price increases the popularity of oral route among patients suffering with acute premature ejaculation. Topical route is to register magnificent growth during the forecast period 2024 to 2032 due to better patient compliance and excellent climax control by delaying the intravaginal ejaculation.

Rise in psychotropic drug use and lack of constructive attitude towards sex determines Asia Pacific market growth

In the present scenario North America holds the largest regional market in premature ejaculation treatment market with 41.5% share. Rising incidence of relationship stress, depression and anxiety in younger population and increasing number of people suffering with illicit drug abuse are responsible for premature ejaculation issues in North America. Domicile of market leaders such as GlaxoSmithkline Plc and Teva Pharmaceutical Industries Ltd., and adherence to effective treatment guidelines drives the premature ejaculation treatment market in Europe. Asia Pacific serves as a lucrative market for premature ejaculation treatment. The factors responsible for the market growth are rise in psychotropic drug use and lack of constructive attitude towards sex. Latin America and Middle East and Africa will project moderate growth during the forecast period 2018 to 2026 on account of developing healthcare infrastructure and rising public health awareness regarding premature ejaculation.

The premature ejaculation market comprises of branded and generic drugs which are prescribed according to the disease prognosis. Inorganic and organic market growth strategies are being employed by market leaders to generate revenue in premature ejaculation treatment market. Quantitative analysis is a very useful tool for mapping the drivers, restraints and opportunities prevalent in the premature ejaculation treatment market. Diverse product portfolio gives a better understanding of the competition prevalent in the market. The pharmaceutical companies commanding the premature ejaculation treatment market are GlaxoSmithkline Plc, Absorption Pharmaceuticals, AstraZeneca, Allergan Plc, Bayer AG, Eli Lilly & Company, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Premature Ejaculation Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Premature Ejaculation Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Premature Ejaculation Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Premature Ejaculation Treatment market?
• Which is the largest regional market for Premature Ejaculation Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Premature Ejaculation Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Premature Ejaculation Treatment market worldwide?